CD40 Deficiency Reduces Alzheimer's Disease Pathology in Mice
Author Information
Author(s): Vincent Laporte, Ghania Ait-Ghezala, Claude-Henry Volmar, Michael Mullan
Primary Institution: The Roskamp Institute
Hypothesis
Is CD40 signaling necessary for the full development of Alzheimer's disease pathology in transgenic mouse models?
Conclusion
Disruption of the CD40 gene in transgenic mice leads to a significant reduction in Alzheimer's disease-like pathology.
Supporting Evidence
- CD40 deficiency led to a 38% to 73% reduction in amyloid plaques in different brain regions.
- Reactive astrocytes were reduced by 34% to 53% in the cortex and hippocampus.
- Microglial activation was decreased by 37% to 65% in the affected brain areas.
Takeaway
When a specific gene called CD40 is turned off in mice that have Alzheimer's, they show less brain damage and perform better on tests.
Methodology
Transgenic mice with disrupted CD40 were compared to controls to assess changes in Alzheimer's disease pathology.
Limitations
The study is limited to mouse models and may not fully translate to human Alzheimer's disease.
Participant Demographics
Transgenic mice, specifically APPsw and PSAPP strains.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website